JP2024547029A - 疼痛の処置における使用のためのペプチド及び方法 - Google Patents

疼痛の処置における使用のためのペプチド及び方法 Download PDF

Info

Publication number
JP2024547029A
JP2024547029A JP2024536410A JP2024536410A JP2024547029A JP 2024547029 A JP2024547029 A JP 2024547029A JP 2024536410 A JP2024536410 A JP 2024536410A JP 2024536410 A JP2024536410 A JP 2024536410A JP 2024547029 A JP2024547029 A JP 2024547029A
Authority
JP
Japan
Prior art keywords
peptide
pain
seq
vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547029A5 (cg-RX-API-DMAC7.html
Inventor
ステファーヌ・ガイヤール
フランシス・カステ
アブデルアジズ・モクリッチ
Original Assignee
タファルジー・セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タファルジー・セラピューティクス filed Critical タファルジー・セラピューティクス
Publication of JP2024547029A publication Critical patent/JP2024547029A/ja
Publication of JP2024547029A5 publication Critical patent/JP2024547029A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024536410A 2021-12-17 2022-12-19 疼痛の処置における使用のためのペプチド及び方法 Pending JP2024547029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306835.6 2021-12-17
EP21306835 2021-12-17
PCT/EP2022/086559 WO2023111348A1 (en) 2021-12-17 2022-12-19 Peptides and methods for use in treating pain

Publications (2)

Publication Number Publication Date
JP2024547029A true JP2024547029A (ja) 2024-12-26
JP2024547029A5 JP2024547029A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=79317102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536410A Pending JP2024547029A (ja) 2021-12-17 2022-12-19 疼痛の処置における使用のためのペプチド及び方法

Country Status (12)

Country Link
US (1) US20250051395A1 (cg-RX-API-DMAC7.html)
EP (1) EP4447991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547029A (cg-RX-API-DMAC7.html)
KR (1) KR20240126864A (cg-RX-API-DMAC7.html)
CN (1) CN118401249A (cg-RX-API-DMAC7.html)
AR (1) AR129864A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022413983A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239578A1 (cg-RX-API-DMAC7.html)
IL (1) IL313183A (cg-RX-API-DMAC7.html)
MX (1) MX2024007301A (cg-RX-API-DMAC7.html)
TW (1) TW202344689A (cg-RX-API-DMAC7.html)
WO (1) WO2023111348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
TW202344689A (zh) 2023-11-16
AU2022413983A1 (en) 2024-06-13
KR20240126864A (ko) 2024-08-21
CA3239578A1 (en) 2023-06-22
MX2024007301A (es) 2024-06-26
CN118401249A (zh) 2024-07-26
AR129864A1 (es) 2024-10-09
US20250051395A1 (en) 2025-02-13
EP4447991A1 (en) 2024-10-23
WO2023111348A1 (en) 2023-06-22
IL313183A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP6680758B2 (ja) 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物
KR20210016434A (ko) 아르기닌-고갈제의 조성 및 이의 암, 비만, 대사 장애 및 관련 합병증 및 동반질환에의 적용
US20250051395A1 (en) Peptides and methods for use in treating pain
JP2022513454A (ja) AIMP2-DX2およびmiR-142の標的核酸を含むベクター、ならびにその使用
US20250213654A1 (en) Peptides and methods for use in treating pain
CN119585299A (zh) 编码抗vegf实体和补体负调节剂的核酸及其用于年龄相关性黄斑变性的治疗的用途
CA3106078A1 (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
JP7428404B2 (ja) Gsx1を使用した脊髄損傷(sci)および脳損傷の処置
KR20120101617A (ko) 알부민과 레티놀 결합 단백질의 융합 단백질
JP7380670B2 (ja) Igf-1-暗号化dna作製物及びhgf-暗号化dna作製物を用いた神経病症治療
RU2597789C2 (ru) Анальгетическое средство на основе плазмидной днк, кодирующей hnp-1, либо hnp-2, либо hnp-3 (варианты)
AU2014233219B2 (en) Methods for treatment of nephrotic syndrome and related conditions
JP2019070001A (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
KR20200074167A (ko) 가바펜티노이드로부터의 간섭이 감소되고 hgf 이형체들을 발현하는 dna 컨스트럭트를 이용하는 신경병증의 치료
US10512698B2 (en) Method for genetic treatment using the AAV-XBP1s/GFP virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis
OA22140A (en) Peptides and methods for use in treating pain.
KR20220016100A (ko) 인슐린 유전자 요법
KR102626543B1 (ko) AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터
WO2008120263A2 (en) Prokineticins receptors antagonists, derivatives and uses thereof
OA22072A (en) Peptides and methods for use in treating pain.
CN117003854A (zh) 用于预防或治疗骨关节炎的蛋白组合物、mRNA组合物及用途
US11464843B2 (en) Use of the salmonella SPP type III secretion proteins as a protective vaccination
KR20130126549A (ko) 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
CN121693571A (zh) 用于治疗中枢神经系统蛋白质病的重组腺相关病毒载体
WO2025259702A1 (en) Method for generating car-t cells in which car expression is coupled with expression of endogenous foxp3, and compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714